Sildenafil citrate (Viagra) in the treatment of men with erectile dysfunction in southern Latin America: A double-blind, randomized, placebo-controlled, parallel-group, multicenter, flexible-dose escalation study

University of Santiago, Chile, CiudadSantiago, Santiago Metropolitan, Chile
International Journal of Impotence Research (Impact Factor: 1.76). 08/2002; 14 Suppl 2(Suppl. 2):S33-41. DOI: 10.1038/sj.ijir.3900896
Source: PubMed


Our objectives were: (1) to determine the efficacy, safety, and tolerability of sildenafil citrate (Viagra) administered to men with broad-spectrum erectile dysfunction (ED) in southern Latin America; and (2) to correlate Rigiscan measurements assessing ED etiology with the investigator's assessment. A total of 141 men with broad-spectrum ED (mean age 57) were enrolled in a randomized, 12-week, double-blind, placebo-controlled, flexible-dose escalation study of sildenafil. After the 12-week treatment period, the mean score for the primary efficacy variables had risen significantly: for the sildenafil group, 66.2% from baseline for question 3 of the International Index of Erectile Function and 77.6% for question 4, vs 15.1% and 21.2% for the placebo group, respectively (P<0.0001). Rigiscan data confirmed investigator assessments of etiology. Headache and flushing, usually mild and transient, were the most common adverse events. Sildenafil was an effective, well-tolerated treatment for men in southern Latin America with broad-spectrum ED.

10 Reads
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Pharmacotherapy of erectile dysfunction comprises oral and local application of drugs. Today, Yohimbin is the only drug listed for this indication. Yohimbin acts via central alpha-receptor blockade and showed a significant effect in a recent double blind study compared to placebo. The centrally acting substances Apomorphin and Trazodone were also tested for their potential use with Apomorphin showing promising results. The orally active phosphodiesterase-V inhibitor Sildenafil acts predominantly on the peripheral side; broad clinical studies demonstrated a significant effect of the drugs compared to placebo. For local use, intraurethral (MUSE) and intracavernous applications are available with PGE1 being the drug the most widely used for the moment. Since many different drugs with various modes of action and different modes of application are being developped at the moment, future pharmacological treatments will allow a more refined approach towards an individually adapted regimen.
    Der Urologe 09/1998; 37(5):503-508. DOI:10.1007/s001200050209 · 0.44 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Descripción: El American College of Physicians desarrolló estas guías clínicas para presentar la evidencia disponible sobre la evaluación hormonal y el tratamiento farmacológico de la disfunción eréctil. Las terapéutica farmacológica actual incluye a los inhibidores de la 5-fosfodiesterasa (PDE-5) como el sildenafil, vardenafil, tadalafil, mirodenafil y udenafil, así como el tratamiento hormonal. Métodos: La literatura publicada sobre este tema fue identificada usando MEDLINE (1966 a mayo del 2007), EMBASE (1980 a la semana 22 del 2007), el Registro Central de Estudios Controlados Cochrane (segunda trimestre del 2007), PsycINFO (1985 a junio del 2007), AMED (1985 a junio del 2007), y SCOPUS (2006). La búsqueda bibligráfica fue actualizada buscando artículos en MEDLINE y EMBASE publicados entre mayo 2007 y abril 2009. Las búsquedas se limitaron a publicaciones en idioma inglés. Esta guía clínica establece el nivel de evidencia y el grado de recomendación utilizando el sistema de graduación de las guías clínicas del American College of Physicians.
  • [Show abstract] [Hide abstract]
    ABSTRACT: Mit dieser Arbeit soll im Zeitalter der Dominanz der oralen Pharmakotherapie bei der Behandlung erektiler Funktionsstrungen eine kritische bersicht ber den aktuellen Stellenwert der operativen Therapie der erektilen Dysfunktion gegeben werden. Als mgliche Therapieoptionen werden die penile Venenchirurgie, die arterielle Revaskularisationschirurgie und die penile Prothesenchirurgie beurteilt.Die Venenchirurgie hat heute aufgrund der Wirksamkeit der oralen und intrakavernsen Therapeutika, bedingt durch den Pathomechanismus der kavernovensen Insuffizienz und durch die publizierten enttuschenden Langzeitergebnisse ihren Stellenwert gnzlich verloren. hnlich verhlt es sich mit den penilen Revaskularisationsoperationen, die heutzutage nur noch bei einem hochselektioniertem Patientengut ihre Berechtigung hat. Wichtige Selektionskriterien sind Patientenalter und Ausschluss eines Diabetes mellitus.Einzig die penile Prothesenchirurgie behauptet gegenber der medikamentsen Therapie der Erektionsstrungen ihren Stellenwert. Hier berzeugen die guten Langzeitergebnisse, die hohe Patienten- und Partnerinnenzufriedenheit bzw. -akzeptanz und die funktionelle Haltbarkeit der in ihrer Mehrzahl dreiteilig, hydraulischen Implantate.In the light of the current domination of oral pharmacotherapy for the treatment of erectile dysfunction, the aim of this paper is to give a critical and up-to-date overview of the possibilities of surgical therapy. We evaluate possible therapy options such as penile vein surgery, arterial revascularisation surgery and penile prosthetics surgery. Today, vein surgery has faded into total insignificance due to the efficiency of oral and intracavernous therapeutics, and as a result of the pathomechanism of cavernoveinous insufficiency and the disappointing long-term results published in the literature. A similar fate has been met by penile revascularisation surgery, which today is performed only in a very limited number patients with strict selection criteria such as age and exclusion of diabetes mellitus. Thus, aside from pharmacotherapy, penile prosthetics is the only surgical therapy option maintaining its significance as a cure for erectile dysfunction. There are convincing long-term results with a high degree of patient and partner satisfaction, high patient acceptance and a good functional durability of the mostly three-part hydraulic implants.
    Der Urologe 09/2003; 42(10):1337-1344. DOI:10.1007/s00120-003-0419-z · 0.44 Impact Factor
Show more